Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
8
September
2026
Clearmind Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following...
Read More
4
September
2026
Clearmind Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Read More
1
September
2026
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Read More
24
August
2026
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support
Read More
13
August
2026
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Read More
11
August
2026
Clearmind Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention ...
Read More
6
August
2026
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Read More
3
August
2026
Clearmind Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems...
Read More
30
July
2026
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability in Part A of its Clinical Trial
Read More
20
July
2026
Clearmind Expands Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion...
Read More
17
July
2026
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Read More
16
July
2026
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Read More
13
July
2026
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Read More
10
July
2026
Clearmind Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery
Read More
7
July
2026
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI
Read More
Next